Clinical predictors of pulmonary hypertension in sarcoidosis
- PMID: 18385166
- DOI: 10.1183/09031936.00175907
Clinical predictors of pulmonary hypertension in sarcoidosis
Abstract
Pulmonary hypertension (PH) adversely affects outcome in sarcoidosis and is an important predictor of mortality in these patients. Early and accurate diagnosis of this complication may improve outcome. The current authors hypothesised that integration of 6-min walk test (6MWT) as part of the evaluation leads to an earlier diagnosis of this complication. A total of 162 patients with sarcoidosis underwent 6MWT. Demographic and pulmonary function results were analysed. Patients were further assessed by echocardiography and right heart catheterisation when clinically indicated. Patients with sarcoidosis-associated PH had significantly decreased results on pulmonary function testing. They also walked shorter distances and desaturated to lower levels on 6MWT. On logistic regression analyses, significant predictors of PH were oxygen saturation <90% on 6MWT (odds ratio (OR) 12.1, 95% confidence interval (CI) 3.66-19.73) and diffusing capacity of the lung for carbon monoxide <60% predicted (OR 7.3, 95% CI 1.98-24.82). Moreover, by combining the results of oxygen saturation at 6 min with those of echocardiography, the ability to correctly predict the presence of PH by right heart catheterisation was improved. Patients with diffusing capacity of the lung for carbon monoxide <60% predicted and oxygen desaturation <90% on 6-min walk test have a high likelihood of pulmonary hypertension and should undergo further evaluation for the presence of this disorder.
Similar articles
-
Pulmonary hypertension in lymphangioleiomyomatosis: prevalence, severity and the role of carbon monoxide diffusion capacity as a screening method.Orphanet J Rare Dis. 2017 Apr 20;12(1):74. doi: 10.1186/s13023-017-0626-0. Orphanet J Rare Dis. 2017. PMID: 28427470 Free PMC article.
-
Sarcoidosis-associated pulmonary hypertension in patients with near-normal lung function.Int J Tuberc Lung Dis. 2013 Mar;17(3):406-11. doi: 10.5588/ijtld.12.0428. Int J Tuberc Lung Dis. 2013. PMID: 23407231
-
Predictors of exercise-induced oxygen desaturation in systemic sclerosis patients with interstitial lung disease.Respir Care. 2014 Jan;59(1):75-80. doi: 10.4187/respcare.02452. Epub 2013 Jun 13. Respir Care. 2014. PMID: 23764864
-
Pulmonary hypertension in chronic lung diseases.J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D109-16. doi: 10.1016/j.jacc.2013.10.036. J Am Coll Cardiol. 2013. PMID: 24355635 Review.
-
Pulmonary hypertension associated with sarcoidosis.Arthritis Res Ther. 2007;9 Suppl 2(Suppl 2):S8. doi: 10.1186/ar2192. Arthritis Res Ther. 2007. PMID: 17767746 Free PMC article. Review.
Cited by
-
Pulmonary hypertension in parenchymal lung disease.Pulm Med. 2012;2012:684781. doi: 10.1155/2012/684781. Epub 2012 Oct 10. Pulm Med. 2012. PMID: 23094153 Free PMC article.
-
Evaluating Riociguat in the Treatment of Pulmonary Arterial Hypertension: A Real-World Perspective.Vasc Health Risk Manag. 2022 Oct 20;18:823-832. doi: 10.2147/VHRM.S383572. eCollection 2022. Vasc Health Risk Manag. 2022. PMID: 36299800 Free PMC article. Review.
-
Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline.Am J Respir Crit Care Med. 2020 Apr 15;201(8):e26-e51. doi: 10.1164/rccm.202002-0251ST. Am J Respir Crit Care Med. 2020. PMID: 32293205 Free PMC article.
-
Comorbidities of sarcoidosis.Ann Med. 2022 Dec;54(1):1014-1035. doi: 10.1080/07853890.2022.2063375. Ann Med. 2022. PMID: 35441568 Free PMC article. Review.
-
Predictive value of pulmonary function testing in the evaluation of pulmonary hypertension in sarcoidosis.Sarcoidosis Vasc Diffuse Lung Dis. 2018;35(4):308-316. doi: 10.36141/svdld.v35i4.6855. Epub 2020 Mar 9. Sarcoidosis Vasc Diffuse Lung Dis. 2018. PMID: 32476918 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical